Adverum Biotechnologies Inc. (NASDAQ: ADVM)
$6.92
-2.0000 ( -22.40% ) 1.4M
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Market Data
Open
$6.92
Previous close
$8.92
Volume
1.4M
Market cap
$144.68M
Day range
$6.92 - $11.79
52 week range
$6.38 - $29.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 1 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |
3 | Insider transactions | 2 | Jun 20, 2024 |
4 | Insider transactions | 2 | Jun 20, 2024 |